Reports

Global Spinal Muscular Atrophy Treatment Market Share, Size, Industry Growth: By Disease Type: Type 1 SMA, Type 2 SMA, Type 3 SMA, Type 4 SMA; By Treatment: Gene Replacement Therapy, Drug Therapy; By Route of Administration: Oral, Intrathecal; By End Use; By Distribution Channel; Regional Analysis; Competitive Landscape; 2023-2028

Global Spinal Muscular Atrophy Treatment Market Outlook

The global spinal muscular atrophy treatment market is expected to grow at a CAGR of 13.80% between 2023 and 2028. Major market drivers are wide prevalence of the disorder, increasing awareness, and technological advancements in diagnostics and treatment.

 

Key Trends in the Market

Spinal muscular atrophy is an genetic disorder which weakens skeletal muscles, resulting in them wasting away. It is caused by gene defects that result in loss of motor neurons involved in controlling muscle movement. No cure has yet been developed for spinal muscular atrophy, but treatments include managing the symptoms and prevention of further complications.

 

  • New product launches in the spinal muscular atrophy treatment market in spite of rare cases of the disorder and high cost of the approved drugs is subjected to fuel the growth of the market.
  • Owing to the severity of the disorder, adoption of expensive drugs developed specifically to treat spinal muscular atrophy has increased which is also contributing to the growth of the market. Research and development have increased by the companies to develop a cure to the spinal muscular atrophy disorder.
  • Fuelled by the internet, increased awareness, and prenatal testing, the knowledge of spinal muscular atrophy is rising, encouraging more potential patients to seek out diagnosis and treatment.

 

Market Analysis

Based on disease type, the market can be divided into Type 1 SMA, Type 2 SMA, Type 3 SMA, and Type 4 SMA. By treatment, the market is bifurcated into gene replacement therapy and drug therapy. On the basis of route of administration, the market is segmented into oral and intrathecal. Based on end use, the market is categorised into hospitals, homecare, and specialty clinics, among others.

 

On the basis of distribution channel, the market is segmented into hospital pharmacies and retail pharmacies, among others. By region, the market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

 

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global spinal muscular atrophy treatment market covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.

 

  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Cytokinetics Inc
  • Others

 

Market Share by Disease Type

Type 1 SMA has accounted for a larger share of the spinal muscular atrophy treatment market among other disease types and is expected to do the same in the forecast period. This is primarily because maximum cases of spinal muscular atrophy disorder are of Type 1.

 

Also known as Werdnig-Hoffmann disease, spinal musical atrophy Type 1 affects infants with symptoms becoming visible before the age of 6 months. Without intervention and treatment, Type 1 SMA can lead to fatalities before the age of 2 years. Due to the wide prevalence of type 1 SMA and timely diagnosis, treatments for Type 1 occupy a leading share of the market.

 

Type 2 SMA is the second most common occurring form of spinal musical atrophy, occurring between the ages of 6 months and 18 months, with progressively worsening symptoms. Spinal muscular atrophy treatment helps extend the lifespan and improve quality of life for patients with Type 2, increasing the demand for the market for SMA treatment.

 

Market Share by Distribution Channels

Hospital pharmacies has been leading the spinal muscular atrophy treatment market on the basis of distribution channels and are expected to be leading the market in the forecast period as well. Medications developed for the treatment of the spinal muscular atrophy are primarily administered intravenously and are advised to be administered by professional doctors or medical experts only. These factors are largely and rapidly contributing to the growth of the hospital pharmacy segment but are acting as a major restraining factor for the growth of the retail pharmacy segment.

 

Competitive Landscape

Biogen Inc is a biotechnology company that develops therapy for the treatment of neurological diseases globally with the help of world’s top neuroscientists and neurologists. It works with an aim to improve the future of medical research. It has its headquarter in Massachusetts, United States and was founded in 1978.

 

Ionis Pharmaceuticals Inc. was established in 1989 and is based out of California in the United States. It is a biotechnology company that is involved in the development and discovery of RNA- targeted therapeutics. They have a drug development platform named antisense technology that is capable of treating illnesses where other treatments prove to be ineffective.

 

F. Hoffmann-La Roche Ltd. was founded in 1896 with headquarters in Basel, Switzerland. It is a healthcare company that provides its products globally. They develop drugs that are used for the treatment of metabolic diseases, cancer, and virus diseases.

 

Other market players include Novartis AG, and Cytokinetics Inc, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Treatment
  • Route of Administration
  • End Use
  • Distribution Channel
  • Region
Breakup by Disease Type
  • Type 1 SMA
  • Type 2 SMA
  • Type 3 SMA
  • Type 4 SMA
Breakup by Treatment
  • Gene Replacement Therapy
  • Drug Therapy
Breakup by Route of Administration
  • Oral
  • Intrathecal
Breakup by End Use
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Biogen Inc.
  • Ionis Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Cytokinetics Inc
  • Others

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Spinal Muscular Atrophy Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Spinal Muscular Atrophy Treatment Historical Market (2018-2022) 
    8.3    Global Spinal Muscular Atrophy Treatment Market Forecast (2023-2028)
    8.4    Global Spinal Muscular Atrophy Treatment Market by Disease Type 
        8.4.1    Type 1 SMA
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2018-2022)
            8.4.1.3    Forecast Trend (2023-2028)
        8.4.2    Type 2 SMA
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2018-2022)
            8.4.2.3    Forecast Trend (2023-2028)
        8.4.3    Type 3 SMA
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2018-2022)
            8.4.3.3    Forecast Trend (2023-2028)
        8.4.4    Type 4 SMA
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2018-2022)
            8.4.4.3    Forecast Trend (2023-2028)
    8.5    Global Spinal Muscular Atrophy Treatment Market by Treatment 
        8.5.1    Gene Replacement Therapy 
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2018-2022)
            8.5.1.3    Forecast Trend (2023-2028)
        8.5.2    Drug Therapy 
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2018-2022)
            8.5.2.3    Forecast Trend (2023-2028)
    8.6    Global Spinal Muscular Atrophy Treatment Market by Route of Administration
        8.6.1    Oral 
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2018-2022)
            8.6.1.3    Forecast Trend (2023-2028)
        8.6.2    Intrathecal
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2018-2022)
            8.6.2.3    Forecast Trend (2023-2028)
    8.7    Global Spinal Muscular Atrophy Treatment Market by End Use
        8.7.1    Hospitals
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2018-2022)
            8.7.1.3    Forecast Trend (2023-2028)
        8.7.2    Homecare
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2018-2022)
            8.7.2.3    Forecast Trend (2023-2028)
        8.7.3    Specialty Clinics
            8.7.3.1    Market Share
            8.7.3.2    Historical Trend (2018-2022)
            8.7.3.3    Forecast Trend (2023-2028)
        8.7.4    Others
    8.8    Global Spinal Muscular Atrophy Treatment Market by Distribution Channel 
        8.8.1    Hospital Pharmacies
            8.8.1.1    Market Share
            8.8.1.2    Historical Trend (2018-2022)
            8.8.1.3    Forecast Trend (2023-2028)
        8.8.2    Retail Pharmacies
            8.8.2.1    Market Share
            8.8.2.2    Historical Trend (2018-2022)
            8.8.2.3    Forecast Trend (2023-2028)
        8.8.3    Others
    8.9    Global Spinal Muscular Atrophy Treatment Market by Region
        8.9.1    Market Share
            8.9.1.1    North America
            8.9.1.2    Europe
            8.9.1.3    Asia Pacific
            8.9.1.4    Latin America
            8.9.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2018-2022)
        9.1.2    Forecast Trend (2023-2028)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2018-2022)
        9.2.2    Forecast Trend (2023-2028)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2018-2022)
        9.3.2    Forecast Trend (2023-2028)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2018-2022)
        9.4.2    Forecast Trend (2023-2028)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2018-2022)
        9.5.2    Forecast Trend (2023-2028)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Value Chain Analysis
12    Competitive Landscape

    12.1    Market Structure
    12.2    Company Profiles
        12.2.1    Biogen Inc. 
            12.2.1.1    Company Overview
            12.2.1.2    Product Portfolio
            12.2.1.3    Demographic Reach and Achievements
            12.2.1.4    Certifications
        12.2.2    Ionis Pharmaceuticals, Inc. 
            12.2.2.1    Company Overview
            12.2.2.2    Product Portfolio
            12.2.2.3    Demographic Reach and Achievements
            12.2.2.4    Certifications
        12.2.3    F. Hoffmann-La Roche Ltd 
            12.2.3.1    Company Overview
            12.2.3.2    Product Portfolio
            12.2.3.3    Demographic Reach and Achievements
            12.2.3.4    Certifications
        12.2.4    Novartis AG 
            12.2.4.1    Company Overview
            12.2.4.2    Product Portfolio
            12.2.4.3    Demographic Reach and Achievements
            12.2.4.4    Certifications
        12.2.5    Cytokinetics Inc 
            12.2.5.1    Company Overview
            12.2.5.2    Product Portfolio
            12.2.5.3    Demographic Reach and Achievements
            12.2.5.4    Certifications
        12.2.6    Others
13    Industry Events and Developments


List of Key Figures and Tables

1.    Global Spinal Muscular Atrophy Treatment Market: Key Industry Highlights, 2018 and 2028
2.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by Disease Type (USD Million), 2018-2022
3.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Disease Type (USD Million), 2023-2028
4.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by Treatment (USD Million), 2018-2022
5.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Treatment (USD Million), 2023-2028
6.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
7.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
8.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by End Use (USD Million), 2018-2022
9.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by End Use (USD Million), 2023-2028
10.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2022
11.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2023-2028
12.    Global Spinal Muscular Atrophy Treatment Historical Market: Breakup by Region (USD Million), 2018-2022
13.    Global Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Region (USD Million), 2023-2028
14.    North America Spinal Muscular Atrophy Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
15.    North America Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
16.    Europe Spinal Muscular Atrophy Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
17.    Europe Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
18.    Asia Pacific Spinal Muscular Atrophy Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
19.    Asia Pacific Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
20.    Latin America Spinal Muscular Atrophy Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
21.    Latin America Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
22.    Middle East and Africa Spinal Muscular Atrophy Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
23.    Middle East and Africa Spinal Muscular Atrophy Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
24.    Global Spinal Muscular Atrophy Treatment Market Structure

Key Questions Answered in the Report

The market is expected to grow at a CAGR of 13.80% between 2023 and 2028.

The major market drivers include prevalence of the disorder, spreading awareness, and technological advancements in diagnostics and treatment.

The key trends of the market are new product launches, increased research and development, prenatal testing, and adoption of expensive drugs.

Key market players include Biogen Inc., Ionis Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Novartis AG, and Cytokinetics Inc, among others.

Spinal muscular atrophy is a genetic disorder in which skeletal muscles are weakened and waste away.

It is caused by gene defects that result in loss of motor neurons involved in controlling muscle movement.

The global spinal muscular atrophy treatment market is segmented based on disease type, treatment, route of administration, end use, distribution channel, and region.

No cure has yet been developed for spinal muscular atrophy, but treatments include drug therapy and gene replacement therapy that are aimed at managing the symptoms and preventing complications.

Purchase Full Report

Mini Report

$ 2199     $1799
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 3199     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$ 4199     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 5199     $4999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER